ANDA 65227, held by Teva Pharms USA. Ceftriaxone Sodium.
As of Nov 15, 2026, ANDA 65227 (Ceftriaxone), held by Teva Pharms USA, was first approved by FDA on Mar 15, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 15, 2007 | Original application | Approved | None posted |
| CeftriaxoneEQ 250MG BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
| CeftriaxoneEQ 500MG BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
| CeftriaxoneEQ 1GM BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
| CeftriaxoneEQ 2GM BASE/VIAL · injectable;intramuscular, intravenous | Ceftriaxone Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
